Fulgent Genetics CFO has shares withheld for taxes

Fulgent Genetics CFO Paul Kim reported a routine tax-related share withholding.

Accepted by SEC EDGAR 01/28/2026 - 05:01 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Fulgent Genetics CFO Paul Kim reported a routine tax-related share withholding. On January 26, 2026, 3,004 shares of Fulgent Genetics common stock were withheld at $27.53 per share to cover tax obligations arising from the vesting of previously granted restricted stock units.

After this withholding, Kim beneficially owned 328,146 shares of common stock in direct form. The transaction was coded "F," indicating a tax withholding event linked to equity compensation rather than an open-market sale.

Insider Trade Summary

Exercise Price or Tax Liability: 3,004 shares

Exercise Price or Tax Liability 1 txn

Insider Kim Paul

Role CFO and Treasurer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,004	$27.53	$83K

Holdings After Transaction: Common Stock — 328,146 shares (Direct)

Holdings Before and After: Common Stock, 331,150 to 328,146 shares (Direct)

Footnotes (1)

1. F1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Fulgent Genetics (FLGT) CFO Paul Kim report?

Paul Kim reported a tax-related withholding of 3,004 Fulgent Genetics shares. The shares were withheld to satisfy tax obligations triggered by the vesting of restricted stock units assumed in a prior merger, rather than sold in an open-market transaction.

On what date did the reported Fulgent Genetics (FLGT) insider transaction occur?

The insider transaction occurred on January 26, 2026. On that date, 3,004 shares of Fulgent Genetics common stock were withheld from CFO Paul Kim to cover tax withholding obligations tied to the vesting of certain restricted stock units.

How many Fulgent Genetics (FLGT) shares were involved in Paul Kim’s Form 4 filing?

The Form 4 filing shows 3,004 Fulgent Genetics common shares were withheld. These shares were applied toward tax withholding obligations created when restricted stock units vested, rather than representing a discretionary sale of stock on the open market.

What price per share is reported in the Fulgent Genetics (FLGT) Form 4 transaction?

The reported price per share in the transaction is $27.53. This value reflects the price used for the 3,004 shares withheld to satisfy CFO Paul Kim’s tax obligations related to the vesting restricted stock unit awards.

How many Fulgent Genetics (FLGT) shares does CFO Paul Kim own after the transaction?

After the tax withholding transaction, Paul Kim beneficially owned 328,146 Fulgent Genetics shares. This figure reflects his direct holdings following the withholding of 3,004 shares for tax purposes associated with the vesting of restricted stock units.

What does transaction code "F" mean in the Fulgent Genetics (FLGT) Form 4?

Transaction code "F" denotes a tax withholding related to equity compensation. In this case, shares were withheld from CFO Paul Kim to cover taxes due when assumed restricted stock units from a prior merger vested, not a voluntary market sale.

What is the origin of the restricted stock units in the Fulgent Genetics (FLGT) Form 4?

The restricted stock units came from awards assumed under a November 7, 2022 merger agreement. That agreement involved Fulgent Genetics, FG Merger Sub, Fulgent Pharma Holdings, and specified stockholders, and the RSU awards were originally reported in a November 9, 2022 Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Paul

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		F		3,004(1)	D	$27.53	328,146	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

	/s/ Paul Kim	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.